key: cord-0854994-ql608kif
authors: To, Kelvin K. W.; Hung, Ivan F. N.; Li, Iris W. S.; Lee, Kar-Lung; Koo, Chi-Kwan; Yan, Wing-Wa; Liu, Raymond; Ho, Ka-Ying; Chu, Kwok-Hong; Watt, Chi-Leung; Luk, Wei-Kwang; Lai, Kang-Yiu; Chow, Fu-Loi; Mok, Thomas; Buckley, Tom; Chan, Jasper F. W.; Wong, Samson S. Y.; Zheng, Bojian; Chen, Honglin; Lau, Candy C. Y.; Tse, Herman; Cheng, Vincent C. C.; Chan, Kwok-Hung; Yuen, Kwok-Yung
title: Delayed Clearance of Viral Load and Marked Cytokine Activation in Severe Cases of Pandemic H1N1 2009 Influenza Virus Infection
date: 2010-03-15
journal: Clin Infect Dis
DOI: 10.1086/650581
sha: 266a8f9a9666a980130726b560f12b764402c994
doc_id: 854994
cord_uid: ql608kif

Background. Infections caused by the pandemic H1N1 2009 influenza virus range from mild upper respiratory tract syndromes to fatal diseases. However, studies comparing virological and immunological profile of different clinical severity are lacking. Methods. We conducted a retrospective cohort study of 74 patients with pandemic H1N1 infection, including 23 patients who either developed acute respiratory distress syndrome (ARDS) or died (ARDS-death group), 14 patients with desaturation requiring oxygen supplementation and who survived without ARDS (survived-without-ARDS group), and 37 patients with mild disease without desaturation (mild-disease group). We compared their pattern of clinical disease, viral load, and immunological profile. Results. Patients with severe disease were older, more likely to be obese or having underlying diseases, and had lower respiratory tract symptoms, especially dyspnea at presentation. The ARDS-death group had a slower decline in nasopharyngeal viral loads, had higher plasma levels of proinflammatory cytokines and chemokines, and were more likely to have bacterial coinfections (30.4%), myocarditis (21.7%), or viremia (13.0%) than patients in the survived-without-ARDS or the mild-disease groups. Reactive hemophagocytosis, thrombotic phenomena, lymphoid atrophy, diffuse alveolar damage, and multiorgan dysfunction similar to fatal avian influenza A H5N1 infection were found at postmortem examinations. Conclusions. The slower control of viral load and immunodysregulation in severe cases mandate the search for more effective antiviral and immunomodulatory regimens to stop the excessive cytokine activation resulting in ARDS and death.

Instead of the anticipated influenza A pandemic with a viral antigenic shift of the surface hemagglutinin subtypes from the seasonal H3 and H1 to either H2 or H5 [1] , a swine origin influenza A H1N1 virus is now replacing the seasonal H1N1 as the cause of the present pandemic. Although such antigenic change is expected to be associated with clinical severity due to the general lack of neutralizing antibody, the crude mortality rate in developed countries was comparable to seasonal influenza. Despite that the majority of the deaths were associated with major underlying illnesses, the higher rate of severe disease in the younger age sector merits more investigations [2] . Moreover, this new virus appeared to have recently jumped from swine to human [3] and replicated more efficiently in the lower respiratory tract of laboratory mammals when compared with the recent seasonal influenza A H1N1 viruses [4] [5] [6] . Although smoking, pregnancy, and morbid obesity were being highlighted as important risk factors for complications in severe cases [7] [8] [9] , the pathogenesis has not been investigated by serial viral load and immunological studies as in the case of fatal influenza A H5N1 infections, which had persistently high viral load and marked proinflammatory cytokine activation [10, 11] .

During the initial containment phase of this pandemic H1N1 2009 influenza epidemic in Hong Kong, all known infected patients were compulsorily isolated in hospitals, which provided the opportunity of taking serial clinical samples [12] . We compared the clinical progression; viral load, cytokine, and chemokine levels; and histopathological findings of laboratory-confirmed cases of different clinical severity. Their implications on the pathogenesis and treatment were discussed.

Seventy-four patients, who were admitted to hospitals in Hong Kong between May and September 2009 and tested positive for pandemic H1N1 2009 influenza virus, were included in the study. Twenty-three patients either developed acute respiratory distress syndrome (ARDS) and/or died (ARDS-death group). In this group, 13 patients (56.5%) died and 18 (78.3%) developed ARDS. Another group of 14 patients developed oxygen desaturation to !90% while breathing room air and required respiratory support, but survived and without developing ARDS (survived-without-ARDS group). Thirtyseven patients isolated in the hospital during this period without respiratory decompensation were randomly selected to represent the mild-disease group.

Methods. This study was approved by the institutional review board of the Hospital Authority of Hong Kong. Clinical findings including history and physical examination, oximetric measurement, hematological, biochemical, radiological, and microbiological investigation results were entered into a predesigned database. Their acute physiology and chronic health evaluation II scores were recorded [13] . ARDS and multiorgan dysfunction syndrome were defined with standard criteria [14] [15] . We observed all groups until death or discharge from hospital.

All 74 patients had the diagnosis of pandemic H1N1 2009 influenza virus infection confirmed either when the pandemic H1 gene was tested positive by reverse-transcription polymerase chain reaction (RT-PCR) or by viral culture in nasopharyngeal or endotracheal specimens. All laboratory procedures were performed as previously reported [16] . Serial nasopharyngeal, and if intubated, endotracheal viral load, were assessed by quantitative PCR of the influenza A virus M gene [17] . The detection limit of this assay was 900 copies of RNA/mL. Blood, urine, and fecal samples were also tested. Oseltamivir resistance was directly detected in the initial positive nasopharyngeal or en-dotracheal sample by RT-PCR and sequencing of a 320-bp fragment of the neuraminidase gene spanning the 274 position for a CrT mutation [18] . The test was repeated in respiratory specimens of patients with persistently high viral load despite oseltamivir treatment. All initial respiratory tract samples were cultured in Madin Darby Canine Kidney cell line with trypsin for 7 days.

The respiratory tract samples on admission were also assessed by multiplex PCR (Luminex) with ResPlex II v2.0 assay (Qiagen) for coinfection with respiratory syncytial virus, influenza B virus, parainfluenza viruses 1-4, human metapneumovirus, enteroviruses, rhinovirus, adenovirus, bocavirus, and coronaviruses NL63, HKU1, 229E, and OC43, in accordance with manufacturer's instructions; and by PCR for Mycoplasma pneumoniae and Chlamydophila pneumoniae [19, 20] . We investigated blood, sputum or endotracheal aspirates, and urine samples bacteriologically, as clinically indicated. Initial urine samples were tested for pneumococcal and legionella antigen by immunochromatographic enzyme immunoassay (Binax). The host immunological response was monitored by the Luminex enzyme immunoassay (Luminex) for 25 different plasma cytokines and chemokines.

Statistical analysis. Clinical, virological, and immunological characteristics were compared. The Fisher exact test and x 2 test were used for categorical variables where appropriate, and the Mann-Whitney U test was used for continuous variables because the data was not normally distributed. Significant risk factors for severe diseases were not further analyzed by multiple logistic regressions due to the small number of cases. Linear regression was used to assess the trend of mean viral load. The Jonckheere-Terpstra trend test was used to compare cytokine or chemokine level with clinical severity. Pearson correlation was used to assess the relationship between the viral load and the absolute lymphocyte count or plasma cytokine levels. SPSS software, version 17.0 for Windows (SPSS), was used for statistical computation. P values !.05 were considered to represent statistically significant differences.

Patients in ARDS-death group were significantly older and more likely to be obese or to have underlying diseases than mild-disease group (Table 1) . Lower respiratory tract symptoms, especially dyspnea, were more common at presentation in ARDS-death group. Comparison between patients in ARDSdeath and survived-without-ARDS group did not reveal significant differences in terms of demographic characteristics, presenting symptoms, and vital signs on admission, except that wheezing was more common in survived-without-ARDS group. Chronic pulmonary disease was more common in survivedwithout-ARDS group than ARDS-death group. Overall, 93.2% of patients received oseltamivir, but nebulized zanamivir was chronic liver disease (in 2), epilepsy (in 1), thalassemia trait (in 1), and hypothyroidism (in 1). For the survived-without-ARDS group, other comorbidities include hypertension (in 5 patients), chronic liver disease (in 1), chronic renal disease (in 1), thalassemia trait (in 1), and eczema (in 1). e Systolic blood pressure, !90 mm Hg; or diastolic blood pressure, !60 mm Hg.

only used in patients with more severe diseases. The median time for initiation of oseltamivir treatment was 5 days after symptom onset in the ARDS-death group, which is later than 4 days in the survived-without-ARDS group and 2 days in the mild-disease group. Three patients in the ARDS-death group did not receive oseltamivir because the diagnosis was made after death. Empirical antibiotics were started in all patients in the ARDS-death and survived-without-ARDS group on admission. The regimen was modified according to bacteriological test results or on an individual basis. As for the initial laboratory parameters at presentation ( Table  2) , neutrophil count, serum alanine transaminase (ALT), creatine kinase, and lactate dehydrogenase levels were higher, but the absolute lymphocyte count was lower in the ARDS-death group than the mild-disease group. ARDS-death group also had a significantly lower total white blood cell, neutrophil, and platelet counts and ALT levels than the survived-without-ARDS group. The nasopharyngeal ( ; ) and en-2 r p 0.0386 P p .009 dotracheal ( ; ) viral loads inversely corre-2 r p 0.1461 P ! .001 lated with the concomitant absolute lymphocyte count.

Initial nasopharyngeal and endotracheal viral loads were similar among patients with different disease severity (Table 3) . Peak viral load occurred within 2 days after symptom onset ( Figure 1A) . Nasopharyngeal viral load decreased after oseltamivir therapy, with the slowest decrease in the ARDS-death group ( Figure 1B ). Viremia was found by RT-PCR in 3 patients in the ARDS-death group and 1 patient in the survived-without-ARDS group. Only 1 stool sample, from a patient in the survived-without-ARDS group, had positive RT-PCR results. All urine samples tested negative by RT-PCR. Oseltamivir resistance with H274Y mutant existing as quasi-species in 3 different specimens were found in 1 patient in the survived-without-ARDS group. Of the 25 cytokines or chemokines assayed, significantly higher levels of granulocyte colony-stimulating factor (G-CSF), interferon (IFN)-a2, interleukin (IL)-1a, IL-6, IL-8, IL-10, IL-15, IFN-g-induced protein 10 (IP-10), monocyte chemoattractant protein (MCP)-1, and tumor necrosis factor (TNF)a were found in the initial samples of ARDS-death group than mild-disease group (Table 3) . Initial IL-17 levels were lower in the ARDS-death group than in the mild-disease group, with the difference approaching statistical significance ( ). P p .074 Compared with the survived-without-ARDS group, significantly higher levels of G-CSF, IL-1a, IL-6, IL-10, IL-15, MCP-1, and TNF-a were found in ARDS-death group. When stratified according to days after symptom onset (days 0-3, days 4-6, and days 7-10), only IL-6, IL-10, and IL-15 levels were higher in those with more severe disease throughout all 3 periods, whereas G-CSF, IL-1a, IL-8, IP-10, and TNF-a levels were higher only during later phase of the disease (Figure 2A-2K) .

Coinfections on presentation occurred in ARDS-death and survived-without-ARDS groups ( Table 2) . Among ARDS-death group, community-acquired methicillin-resistant Staphylococcus aureus was cultured from blood and pleural fluid samples from 1 patient and from sputum samples from another patient. Methicillin-susceptible S. aureus and Pseudomonas species were cultured from 2 and 1 patient respectively. One patient had pulmonary tuberculosis, with a sputum smear positive for acidfast bacilli and PCR positive for Mycobacterium tuberculosis. This same patient also had pneumococcal antigenuria. For survived-without-ARDS group, Haemophilus influenzae and Pseudomonas species were found in 1 patient each. Rhinovirus was detected in 2 patients from ARDS-death group and 1 patient from survived-without-ARDS group. Other respiratory viruses, C. pneumoniae, M. pneumoniae, and Legionella species were not detected.

Complications were most common in the ARDS-death group ( Table 2) . Five patients (21.7%) had clinical, laboratory, and echocardiographic evidence of myocarditis; 3 of these cases were confirmed at postmortem examination ( Figure 3E ). Multiorgan dysfunction syndrome predominantly occurred in ARDS-death group (69.6%). One patient in the ARDS-death group developed both ventilator associated pneumonia and Enterobacter cloacae bacteremia. No rhabdomyolysis or encephalopathy was found.

The median time of death was 10 days after symptom onset (range, 3-33 days). The cause of death was respiratory failure in 11 patients (including 5 patients with secondary bacterial pneumonia, 4 patients with myocarditis), heart failure due to myocarditis in 1 patient, and Escherichia coli bacteremia in 1 patient. Postmortem examination or paramortem tissue biopsies were performed in 5 patients who died between day 3 and 28 after symptom onset. Examination of 4 patients who died around day 10 after symptom onset showed acute exudative diffuse alveolar damage with proteinaceous exudate in alveolar space and interstitial infiltrate in alveolar septa ( Figure  3A ). One patient, who died on day 28 after symptom onset, had fibroproliferative changes of diffuse alveolar damage (Figure 3B) . Reactive hemophagocytosis was found in the lymph node or bone marrow of 2 patients ( Figure 3F ). Lymphoid atrophy was also observed ( Figure 3D ). Three cases had changes of acute lymphocytic myocarditis ( Figure 3E ). One case had thrombosis in branches of pulmonary artery ( Figure 3C ) and splenic artery with wedge-shaped infarct despite heparinization while undergoing extracorporeal membrane oxygenation.

Clinical studies on the severity of pandemic H1N1 2009 influenza virus infection have not utilized patients with mild disease except for pregnant patients [8] . Laboratory study in cell lines showed that this virus was similar to recent seasonal influenza A H1N1 virus in terms of viral replication rate and the ability to induce proinflammatory cytokines but markedly inferior to that of influenza A H5N1 virus [11, 21] . However, unlike seasonal influenza virus, which replicates mainly in the upper respiratory tract, challenge studies in mammals showed that the pandemic virus can replicate to a high level in both the upper and lower respiratory tracts [4] [5] [6] . The findings of ARDS with postmortem findings of diffuse alveolar damage, reactive hemophagocytosis and lymphoid atrophy in our deceased patients were compatible with a cytokine storm and have similarly been reported in H5N1 infection [10] . Therefore, we studied the clinical characteristics, serial viral load in the respiratory specimens, and plasma levels of cytokines and chemokines in the 3 groups of patients with different levels of disease severity.

Irrespective of disease severity, the viral load already peaked within 2 to 3 days of symptom onset. Animal experiments and clinical studies showed that viral load increased steadily within 48 h after inoculation when the host failed to mount any innate immune response [22] . Once innate immune response was mounted, the viral load reached a plateau. Due to the later presentation of the severe cases, data on the viral load in the initial days after symptom onset were scarce. Thus, the nasopharyngeal viral load at presentation appeared to be slightly lower in the more severe groups. The later presentation of the more severe cases might have allowed more time for the recruitment of cytotoxic T lymphocyte response specific to the highly homologous nucleoprotein antigen present in all influenza A viruses which can suppress the viral load.

A slower decline in viral shedding was observed in all severe patients in the ARDS-death group or the survived-without-ARDS group than in the mild-disease group ( Figure 1A and  1B) . The finding could be related to a less effective innate and adaptive immune response together with a delay in starting antiviral therapy due to a later presentation. Fatal cases of H5N1 infection had persistently high viral load due to oseltamivir resistance [23] , but oseltamivir resistance was not responsible for the slower rate of decline in viral shedding in our series, because only 1 patient was infected with oseltamivir-resistant virus who eventually survived without complication by ARDS.

Although uncontrolled viral infection was unlikely to be the only cause of death or ARDS, antiviral therapy that can suppress the viral load more rapidly, such as intravenous zanamivir [24] , and neutralizing antibody in convalescent plasma or hyperimmune intravenous immunoglobulin should be considered in randomized, control trials for the treatment of severe cases. Such strategy may accelerate clearance of their viral load, which may also reduce the excessive cytokine release.

As for the role of proinflammatory cytokines or chemokines, which can have both antiviral activity and damage on host tissue, highest levels were seen in the ARDS-death group. Plasma cytokine and chemokine profiles of the severe group were consistent with the challenged macaque model, which showed elevated levels of MCP-1 and IL-6 in their inflamed lungs [6] . When stratified by time after symptom onset, there was a significant correlation between disease severity and the level of IL-6, IL-10, and IL-15 throughout the initial 10 days after symptom onset. Correlation between higher IL-6 levels and severe influenza infection has been well established in both animal and in human [26] [27] , but this correlation has not been reported for IL-10 and IL-15. As an anti-inflammatory cytokine, IL-10 is essential in dampening inflammatory response to prevent excessive host damage. Of interest, IL-10 deficiency was shown to be protective in influenza infection in mice, and high IL-10 production in elderly was associated with poorer antibody response to influenza vaccine [27, 28] . IL-15 level has been reported to be elevated among many bacterial and viral infections [29] . Despite being regarded as a proinflammatory cytokine, recent animal model suggested that high levels of IL-15 may actually decrease the level of antibody against influenza [30] . In contrast, IL-17 was lower in the more severe groups, consistent with previous studies which showed that IL-17 might help to protect against lethal influenza [31] . The use of immunomodulator in the treatment of influenza is still controversial but appeared effective when an antiviral is given concomitantly [32] .

In our series, lymphopenia was more common among patients with severe disease, as seen in SARS coronavirus infection [33] . Furthermore, an inverse correlation between lymphocyte count and viral load in both the nasopharyngeal and endotracheal specimens was observed. Similar findings were found in patients with H5N1 infection [26] . Lymphopenia in infection may be due to lymphocyte apoptosis mediated by TNF-a, which was also elevated. Another possibility was direct infection of T lymphocytes, as shown in histopathological studies of H5N1 infection [34] .

Evidence of bacterial coinfection was present in 30.4% of our most severe cases, which resembled the rate in another autopsy study [35] . However, bacterial isolates in our series have been covered adequately during the course of hospitalization. Other nonpulmonary complications, such as myocarditis, might have contributed to the mortality. Chronic pulmonary diseases and exacerbation of underlying pulmonary comorbidities were over-represented in the survived-without-ARDS group, suggesting that although these patients required oxygen supplementation, their prognosis was usually better than those who have respiratory decompensation due to viral pneumonitis. Thrombotic phenomena such as thrombosis in branches of pulmonary artery and splenic artery leading to wedged splenic infarct were found, which resembled those reported during the 1918 pandemic [36] . Although abdominal symptoms were reported to be an important clinical manifestation, and although an in vitro study showed that this virus could replicate to a high level in the intestinal cell line Caco-2 [21] , gastrointestinal symptoms were not prominent in our cases. As in patients who developed cytokine storm, shock requiring inotropic support and multiorgan dysfunction syndrome were frequent.

Our study had several limitations. The frequent taking of clinical samples was prohibitive to the enrollment of children, and even adult patients occasionally refused serial nasopharyngeal or blood sampling. Viral load can be affected by minor differences in sampling technique, but this problem will affect all groups. The use of nasopharyngeal swabs may result in a lower viral load than nasopharyngeal aspirate, but very few of our samples were obtained by swabs. Because of the changing clinical status of individual patients, treatment regimen could not be unified and may confound the viral load and immunological profiles. In summary, a slower control of viral load and dysregulated cytokine profile are important in the pathogenesis of severe disease by this new pandemic virus. Preexisting immune impairment due to underlying diseases or genetic susceptibility in apparently immunocompetent cases should be investigated. Our findings mandate interventional studies of severe cases by other antiviral and immunomodulatory strategies.

Avian influenza virus infections in humans

Severe respiratory disease concurrent with the circulation of H1N1 influenza

Geographic dependence, surveillance, and origins of the 2009 influenza A (H1N1) virus

Pathogenesis and transmission of swine-origin 2009 A(H1N1) influenza virus in ferrets

Transmission and pathogenesis of swine-origin 2009 A(H1N1) influenza viruses in ferrets and mice

In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses

Severe human influenza infections in Thailand: oseltamivir treatment and risk factors for fatal outcome

Novel Influenza A (H1N1) Pregnancy Working Group. H1N1 2009 influenza virus infection during pregnancy in the USA

Intensive-care patients with severe novel influenza A (H1N1) virus infection-Michigan

Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus

Cytokine profiles induced by the novel swine-origin influenza A/H1N1 virus: implications on treatment strategies

Prevention of nosocomial transmission of swine-origin pandemic influenza virus A/H1N1 by infection control bundle

APACHE II: a severity of disease classification system

The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination

The distinct clinical profile of chronically critically ill patients: a cohort study

Confirmation of the first Hong Kong case of human infection by novel swine origin influenza A (H1N1) virus diagnosed using ultrarapid, real-time reverse transcriptase PCR

Viral load in patients infected with pandemic H1N1 2009 influenza virus

Oseltamivir-resistant influenza A pandemic (H1N1) 2009 virus

Detection of Mycoplasma pneumoniae by two polymerase chain reactions and role of M. pneumoniae in acute respiratory tract infections in pediatric patients

Identification of Chlamydia pneumoniae by DNA amplification of the 16S rRNA gene

Differential susceptibility of different cell lines to swine-origin influenza A H1N1, seasonal human influenza A H1N1, and avian influenza A H5N1 viruses

Cutting edge: stealth influenza virus replication precedes the initiation of adaptive immunity

Oseltamivir resistance during treatment of influenza A (H5N1) infection

H1N1 pneumonitis treated with intravenous zanamivir

Severe seasonal influenza in ferrets correlates with reduced interferon and increased IL-6 induction

Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia

IL-10 deficiency unleashes an influenza-specific Th17 response and enhances survival against highdose challenge

High interleukin-10 production is associated with low antibody response to influenza vaccination in the elderly

Interleukin 15: biology and relevance to human disease

High dose of plasmid IL-15 inhibits immune responses in an influenza non-human primates immunogenicity model

The roles of IL-17A in inflammatory immune responses and host defense against pathogens

Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virus

Viral loads in clinical specimens and SARS manifestations

H5N1 infection of the respiratory tract and beyond: a molecular pathology study

Bacterial coinfections in lung tissue specimens from fatal cases of 2009 pandemic influenza A (H1N1)-United States

The pathology of influenza virus infections

We acknowledged the contributions of the members of the pandemic H1N1 study which included